Passage Bio is actively advancing its differentiated preclinical research project for Huntington's disease.
Show original
The project has made significant progress, and the company expects to complete the selection of clinical candidate drugs in the second half of 2026. This important milestone marks a key step forward for the company in the field of gene therapy research and development in neuroscience. The identification of candidate drugs will lay a solid foundation for subsequent clinical development and is expected to bring new hope for treatment to Huntington's disease patients.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Meme coin "Lobster" market cap briefly surged to $10 million, hitting a new high with a 24-hour increase of 250%
Chaincatcher•2026/03/09 10:04
PancakeSwap Skills supports one-click trading and management of four.meme graduation tokens
ForesightNews•2026/03/09 09:59
Brent crude oil falls below $100 per barrel
Cointime•2026/03/09 09:58
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$67,999.42
+0.22%
Ethereum
ETH
$2,005.52
+2.08%
Tether USDt
USDT
$1
-0.00%
BNB
BNB
$627.94
+1.17%
XRP
XRP
$1.35
-0.59%
USDC
USDC
$1.0000
-0.01%
Solana
SOL
$84.11
+0.97%
TRON
TRX
$0.2876
+0.31%
Dogecoin
DOGE
$0.09054
+0.42%
Cardano
ADA
$0.2563
+0.62%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now